Letters Drug treatment in Parkinson’s disease

The BMJ, take heed: almost all studies have some degree of bias

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5490 (Published 21 October 2015) Cite this as: BMJ 2015;351:h5490
  1. Martin Toal, pharmaceutical physician1
  1. 1Wokingham, UK
  1. martin.toal{at}mac.com

In the section on cost effectiveness of initial drug treatment in Parkinson’s disease, Muzerengi and Clarke say that health economic studies on drugs for Parkinson’s disease were “funded by drug companies and results may be biased.” …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe